When blood cancer cells break through the bone and multiply, tumor cells become dangerously diverse and the immune response in the region changes, researchers report. The detailed insights into cancer ...

The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor ...

A thyroglobulin antibody (TgAb) test looks for certain antibodies that attack the thyroid. The presence of TbAb in high levels may indicate that someone has an autoimmune condition. To conduct a ...

Emerging Bispecifics in Multiple Myeloma: Real-World Insights and Treatment Strategies EP: 2 . Navigating Adverse Events in Bispecific Antibody Therapies: Infection Prevention and Management ...

Multiple myeloma is a rare blood cancer that develops in the plasma cells, which are white blood cells that help you fight infection by making antibodies. Multiple myeloma starts in the plasma ...

Myeloma, or multiple myeloma, is a cancer affecting a particular type of blood cells, called plasma cells. Myeloma is most common in people over 60 and is characterized by the accumulation of ...

I mean, with all the development we've seen in multiple myeloma, there are a few areas ... areas who may not have access even to bispecific antibodies, which you can argue can be given without ...

We're excited in the multiple myeloma that we continue to work in ... we have three ways of targeting this receptor, including the antibody direct conjugate, as well as the chimeric antigen ...

Recovery from multiple myeloma leads to a renewed sense of purpose and determination, with hope found in small victories. The Bells of Hope community provides support and inspiration, fostering unity ...

Prophylactic tocilizumab has the potential to decrease cytokine release syndrome and neurotoxicity for bispecific antibodies, explained Robert Rifkin, MD, FACP, a medical oncologist and ...